Description
Tadalafil is an oral medication that helps improve erections and ease urinary symptoms of benign prostatic hyperplasia (BPH) by enhancing blood‑flow signaling. A higher‑dose formulation (Adcirca®) is approved for pulmonary arterial hypertension (PAH). It requires a prescription.
Half‑life & pharmacology
- Oral half‑life: ~17.5 hours
- Duration window: Up to 36 hours of responsiveness for on‑demand ED dosing (individual variability).
- Onset: Typically 30–60 minutes for on‑demand use; daily low‑dose provides steady coverage.
How it works (mechanism)
- PDE‑5 inhibition: Tadalafil blocks the PDE‑5 enzyme that breaks down cGMP.
- NO–cGMP pathway: With sexual stimulation, nitric oxide (NO) increases cGMP, relaxing smooth muscle in the corpus cavernosum (penile tissue) → more blood flow → erection.
- Lower urinary tract (BPH): Smooth‑muscle relaxation in the prostate/bladder/urethra may improve flow and reduce symptoms.






There are no reviews yet.